KB Home (NYSE: KBH) is not out of the weeds, with its revenue contracting, orders and backlog declining, and margins under pressure, but these forces are already priced into its stock. Housing market woes, inflation, and high interest rates are no secret.
The market has had ample opportunity to adj.... |
Good MorningStocks finished mixed Wednesday, with the Dow notching a gain while the S&P 500 and Nasdaq closed lower as the tech selloff continued. Major ETFs tied to the S&P 500 and Nasdaq 100 reversed early strength, while lower oil prices helped lift airline stocks and supported a rotation away from some recent AI winners.
Micron was the post-close standout after reporting record fiscal third-quarter results and stronger guidance, with AI-driven memory demand reinforcing the case for firmer pricing and tighter supply. Shares rose after hours. Broadcom also gained after OpenAI unveiled Jalapeño, an AI inference chip developed with Broadcom, while IBM moved higher after joining OpenAI’s cybersecurity partner program. Still, pressure remained on Oracle and Palantir, both caught in the broader debate over AI spending, valuation, and earnings quality.
Outside megacap tech, homebuilders rallied after Congress passed a bipartisan housing package aimed at boosting supply and lowering construction costs, though the bill still faced a White House signing delay. American Airlines, United and JetBlue climbed as falling fuel costs improved sentiment toward carriers. Bath & Body Works gained from a new Ulta Beauty partnership, while AT&T remained under regulatory scrutiny as California officials pushed back on its copper-network retirement plans. Featured: Why I broke this rule (Ad) 
| Construction | |
KB Home (NYSE: KBH) is not out of the weeds, with its revenue contracting, orders and backlog declining, and margins under pressure, but these forces are already priced into its stock. Housing market woes, inflation, and high interest rates are no secret.
The market has had ample opportunity to adj... Read the Full Story |
| From Our Partners | | The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings research points to the first half of 2026 as a particularly rough stretch for certain holdings.
Some of America's most popular stocks could take serious damage as a radical market shift plays out. Analysts at Weiss Ratings have identified five names you may want to remove from your portfolio before this unfolds.
If any of these are in your portfolio, now is the time to review your positions. | | See the 5 stocks to avoid |
| Technology | |
Meta Platform’s (NASDAQ: META) last earnings report disappointed investors, leading shares to fall more than 8% to $611 afterward. This drop has so far indicated the start of a larger slide for the stock, as Meta has continued to tumble, recently falling below $575.
The company’s increased capital... Read the Full Story |
| Auto/Tires/Trucks | |
Shares of Tesla Inc. (NASDAQ: TSLA) are down about 15% from the May high and are starting to take a shape that investors won't want to see. The broader narrative around the company has been getting more interesting by the month, from the Wall Street hype around the company’s full self-driving (FSD)... Read the Full Story |
| From Our Partners | | SpaceX and xAI just completed a $1.25 trillion merger - and Musk may no longer need data centers from Microsoft, Amazon, or Google.
Tech expert and angel investor Jeff Brown has identified one chipmaker, 148 times smaller than NVIDIA, that is set to supply Musk with 5 billion chips over the next two years. Brown brings decades of senior executive experience at Qualcomm, Juniper Networks, and NXP Semiconductors to this call. | | Watch Jeff Brown's urgent briefing before it comes down |
| Energy | |
Nano Nuclear (NASDAQ: NNE) appears to be the right company for the right time. The company has a goal of building a vertically integrated nuclear business. This goes beyond microreactors to include fuel fabrication, transportation, and other parts of the nuclear supply chain.
The case for nuclear e... Read the Full Story |
| Auto/Tires/Trucks | |
The first round of peace talks aimed at ending the Iran war are in the books, but the damages stemming from the global oil supply shock will linger for years to come.
Prices for Brent crude, the benchmark for two-thirds of the world’s oil, have moderated from their one-year high of around $114 per ... Read the Full Story |
| From Our Partners | | Why Some Traders Skip Stocks Entirely
You don't need a big account to trade options.
In fact, options can give you up to 12 times the leverage of stocks — with a fraction of the capital tied up.
This free guide lays it all out in plain English — from A to Z, with step-by-step examples you can follow in your own account. | | Normally $29.97. Today it's free. Grab your copy now. |
| Retail/Wholesale | |
Several stocks spanning the gamut of high dividend yields to high dividend growth just added more juice to their payments. These stocks hold yields that stretch above 13% at the high end, while also seeing recent dividend increases of up to 14%. This leaves investors with multiple options for how t... Read the Full Story |
| Technology | |
From quantum computing to artificial intelligence to clothing, company insiders are making moves in three key names. This includes sales of a quantum stock that recently popped 50% in two days and a semiconductor industry behemoth posting big-time returns. Meanwhile, insiders are purchasing a cloth... Read the Full Story |
| Technology | |
On June 23, 2026, the equity market delivered a sharp reminder that technology leadership is inseparable from global trade policies. Shares of the Dutch lithography giant ASML Holding N.V. (NASDAQ: ASML) declined by 7.82%, representing a pullback from the all-time high of $1,929.68 reached on June ... Read the Full Story |
| Markets | |
A combination of a weaker U.S. dollar, a push among retail and institutional investors alike toward international investments, and increasing demand for AI exposure have all positioned South Korea as a country to watch in 2026. Companies like Samsung Electronics and SK Hynix are at the center of th... Read the Full Story |
| Technology | |
Investors looking for high-growth AI infrastructure opportunities have likely watched the recent volatility in Super Micro Computer, Inc. (NASDAQ: SMCI) with a mix of intrigue and anxiety. The central question is whether Supermicro's recent decline represents a warning sign or a buying opportunity.... Read the Full Story |
| Thursday's Early Bird Stock Of The Day Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity. It also provides oncology products, including Alimta, Cyramza, Erbitux, Jaypirca, Retevmo, Tyvyt, and Verzenio. In addition, the company offers Olumiant for rheumatoid arthritis, atopic dermatitis, severe alopecia areata, and COVID-19; Taltz for plaque psoriasis, psoriatic arthritis, ankylosing spondylitis, and non-radiographic axial spondylarthritis; Omvoh for ulcerative colitis; Cymbalta for depressive disorder, diabetic peripheral neuropathic pain, generalized anxiety disorder, fibromyalgia, and chronic musculoskeletal pain; Ebglyss for severe atopic dermatitis; and Emgality for migraine prevention and episodic cluster headache. Further, it provides Cialis for erectile dysfunction and benign prostatic hyperplasia; and Forteo for osteoporosis. It has collaborations with Incyte Corporation; Boehringer Ingelheim Pharmaceuticals, Inc.; F. Hoffmann-La Roche Ltd and Genentech, Inc.; Biologics, Inc., AbCellera Biologics Inc.; and Chugai Pharmaceutical Co., Ltd. The company was founded in 1876 and is headquartered in Indianapolis, Indiana. | Should I Buy Eli Lilly and Company Stock? LLY Bull and Bear Case Explained
These insights were generated using artificial intelligence. They are based on proprietary MarketBeat data, news articles, and custom LLM A.I. algorithms. This analysis of Eli Lilly and Company was last updated on Tuesday, June 23, 2026 at 6:05 PM.
Eli Lilly and Company Bull Case -
The current stock price is around $1,100, reflecting strong market confidence in the company's growth potential.
-
Eli Lilly and Co reported impressive quarterly earnings, with earnings per share significantly exceeding analyst expectations, indicating robust financial health.
-
The company achieved a remarkable year-over-year revenue growth of over 55%, showcasing its ability to expand and capture market share effectively.
-
With a return on equity of over 105%, Eli Lilly and Co demonstrates efficient use of shareholder equity to generate profits, which is attractive to investors.
-
The company has a manageable debt-to-equity ratio, suggesting a balanced approach to leveraging debt for growth while maintaining financial stability.
Eli Lilly and Company Bear Case -
The dividend yield is relatively low at 0.6%, which may not attract income-focused investors looking for higher returns from dividends.
-
The company's payout ratio is around 24.58%, indicating that a significant portion of earnings is retained for reinvestment, which could limit immediate returns to shareholders.
-
Despite strong revenue growth, the pharmaceutical industry is highly competitive, and future earnings may be impacted by market pressures and regulatory challenges.
-
Investors may be concerned about the sustainability of recent earnings growth, as it may not be easily replicated in future quarters.
-
The current economic environment poses risks, including potential changes in healthcare policies that could affect profitability and market access for Eli Lilly and Co's products.
| | View Today's Stock Pick |
|
| |
|
|
